Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: AurumRabosa who wrote (914)	4/5/2000 8:02:00 AM
From: Jim Oravetz	Read Replies (3) \| Respond to of 52153

SAN FRANCISCO, April 4 /PRNewswire/ -- With the "biotech century" just beginning, the biotech bulls ran strong during the first two-and-a-half monthsof the year until the bears took over, aided by Clinton/Blair's unnecessarycomments on genomic patenting. During the first quarter of 2000, the industrysaw its largest private placement ever (Orchid BioSciences, $72 million); itssecond largest follow-on (Celera [CRA], $983 million); 9 biotech companiesgoing public (raising $1.1 billion -- almost twice the amount raised by IPOsin all of 1999); and a flurry of companies filing for IPOs. The industry raised $12 billion in the first quarter of 2000, anincredible 420 percent increase from the same quarter last year($2.3 billion). "For an industry which raised only $5 billion in each year'96, '97 and '98, raising $12 billion this quarter is awesome," saidG. Steven Burrill, CEO of Burrill & Company, a private merchant bank focusedsolely on the life sciences. SNIP..... prnewswire.com Jim